novamind stock

Why some stocks are undervalued A lot of things go into determining a company’s share price, but in a young emerging industry like psychedelics, many of the traditional measurements…
$13 million give or take Earlier this week the law firms of Wolf Haldenstein Adler Freeman & Herz and The Portnoy Law Firm both announced class-action lawsuits against psychedelics…
Cedar Clinical Research Novamind (NM.C) announced today it’s increasing its investment in the Australian-based drug company Bionomics (BNO.ASX). The company is focused primarily on anxiety, PTSD, and central nervous…
Cluster B Several psychedelics companies are out to target depression, anxiety, PTSD, and substance use disorder – but surprisingly we don’t hear much about personality disorders.   Despite an…
Early money Generating revenue as a new company is almost always difficult. It typically takes time to build up a loyal customer base, execute marketing campaigns and create awareness…
Earlier this month I wrote a piece on Field Trip (FTRP.C) scaling their ketamine clinics after a huge $95M raise. I liked their business model, and Novamind’s (NM.C) is…